GlassScriptPhysician profile
Rose Ballard
NPI 1932503919
$2,936.30
in general payments reported to CMS, 2019-2025
34 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $275 · 2022: $639 · 2023: $905 · 2024: $872 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $606.70 | 2022-2025 | |
| Ge Healthcare | $343.77 | 2021-2025 | |
| Boston Scientific Corporation | $140.40 | 2024 | Watchman Access System |
| Csl Behring | $137.92 | 2022-2023 | Kcentra |
| Astrazeneca Pharmaceuticals LP | $126.16 | 2021-2023 | Andexxa |
| Alexion Pharmaceuticals, INC. | $125.06 | 2021-2023 | Ultomiris |
| Pfizer INC. | $123.96 | 2023-2024 | |
| Novo Nordisk INC | $123.41 | 2021 | |
| Neurelis, INC. | $103.36 | 2022-2024 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $91.83 | 2021-2024 | Austedo Xr |
| Ucb, INC. | $88.87 | 2021-2025 | Zilbrysq, Fintepla |
| Catalyst Pharmaceuticals, INC. | $88.33 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $85.16 | 2022-2023 | Onpattro |
| Corium, LLC | $72.83 | 2022-2023 | Adlarity |
| Biohaven Pharmaceutical Holding Company LTD. | $71.82 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $59.67 | 2022-2024 | Ingrezza |
| Lundbeck LLC | $56.48 | 2022-2024 | Vyepti |
| Amgen INC. | $47.74 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $46.99 | 2022-2023 | Nuplazid |
| Avion Pharmaceuticals | $39.43 | 2021-2023 | Dhivy |
| Lilly USA, LLC | $34.63 | 2022-2024 | Amyvid |
| Insightec,INC | $34.41 | 2023-2024 | Exablate |
| Takeda Pharmaceuticals U.S.A., INC. | $32.74 | 2023 | |
| Abbott Laboratories | $32.32 | 2024-2025 | Optis, Ultreon |
| Tanabe Pharma America, INC. | $29.52 | 2024 | |
| Stryker Corporation | $28.10 | 2024 | Trevo |
| Acorda Therapeutics, INC | $25.74 | 2023 | Inbrija |
| Horizon Therapeutics Plc | $25.68 | 2023 | Uplizna |
| Eisai INC. | $25.67 | 2024 | |
| Nevro Corp. | $21.61 | 2024 | Senza |
| Merz Pharmaceuticals, LLC | $19.83 | 2024 | Xeomin |
| Amylyx Pharmaceuticals, INC. | $16.32 | 2023 | Relyvrio |
| Xeris Pharmaceuticals, INC. | $15.01 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Ballard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.